Porphyrins, a class of heterocyclic macrocycles, have garnered significant attention for their potential antiviral properties, particularly against human immunodeficiency virus (HIV). This review explores how porphyrins and their derivatives inhibit HIV replication, focusing on their interactions with key viral components, including reverse transcriptase, protease, and integrase. In addition, the review highlights the role of porphyrins in photodynamic therapy (PDT) as a novel approach to targeting HIV-infected cells. Recent studies have demonstrated that metalloporphyrins, in particular, exhibit enhanced antiviral activity due to their unique structural and electronic properties. Despite promising in vitro and preclinical results, challenges such as cytotoxicity, bioavailability, and resistance mechanisms remain unaddressed. This review provides a comprehensive analysis of the current state of research on porphyrins as anti-HIV agents, emphasizing their potential as a therapeutic strategy and identifying key areas for future investigation. The findings underscore the importance of porphyrins in the ongoing search for effective antiviral therapies against HIV.
MahajanAP, SaylesJN, PatelVA, et al.Stigma in the HIV/AIDS epidemic: A review of the literature and recommendations for the way forward. AIDS, 2008; 22(Suppl 2):S67–S79; doi: 10.1097/01.aids.0000327438.13291.62
3.
EngelmanA, CherepanovP. The structural biology of HIV-1: Mechanistic and therapeutic insights. Nat Rev Microbiol, 2012; 10(4):279–290; doi: 10.1038/nrmicro2747
SardoL, ParolinC, YoshidaT, et al.Editorial: Novel insights into a functional HIV cure. Front Microbiol, 2021; 12:797570; doi: 10.3389/fmicb.2021.797570
6.
HirotoS, MiyakeY, ShinokuboH. Synthesis and functionalization of porphyrins through organometallic methodologies. Chem Rev, 2017; 117(4):2910–3043; doi: 10.1021/acs.chemrev.6b00427
7.
FaH, YinW, HouC, et al.Photochemical and electrochemical properties of porphyrin dimers containing an anhydride spacer. J Coord Chem, 2009; 62(7):1151–1161; doi: 10.1080/00958970802382875
GujarathiPB. Recent emerging applications of porphyrins and Metalloporphyrins and their analogue in diverse areas. Pharma Innovation, 2020; 9(4):80–86; doi: 10.22271/tpi.2020.v9.i4b.4571
10.
Thomas-MooreBA, del ValleCA, FieldRA, et al.Recent advances in nanoparticle-based targeting tactics for antibacterial photodynamic therapy. Photochem Photobiol Sci, 2022; 21(6):1111–1131; doi: 10.1007/s43630-022-00194-3
11.
SharmaD, SenguptaD. Porphyrins in Photodynamic Therapy: A Review. ChemRxiv, 2023; doi: 10.26434/chemrxiv-2023-j1tc1
12.
TianZ, LiH, LiuZ, et al.Enhanced photodynamic therapy by improved light energy capture efficiency of porphyrin photosensitizers. Curr Treat Options Oncol, 2023; 24(9):1274–1292.
13.
ChenS, HuangB, TianJ, et al.Advancements of porphyrin-derived nanomaterials for antibacterial photodynamic therapy and biofilm eradication. Adv Healthc Mater, 2024; 13(27):e2401211; doi: 10.1002/adhm.202401211
14.
SavelyevaIO, ZhdanovaKA, GradovaMA, GradovOV, BraginaNA. Cationic porphyrins as antimicrobial and antiviral agents in photodynamic therapy. Curr Issues Mol Biol, 2023; 45(12):9793–9822; doi: 10.3390/cimb45120612
15.
HollenbaughJA, MungerJ, KimB. Metabolite profiles of human immunodeficiency virus infected CD4+ T cells and macrophages using LC–MS/MS analysis. Virology, 2011; 415(2):153–159; doi: 10.1016/j.virol.2011.04.007
16.
GottfriedJM. Surface chemistry of porphyrins and phthalocyanines. Surf Sci Rep, 2015; 70(3):259–379; doi: 10.1016/j.surfrep.2015.04.001
17.
AfonsoSG, Enríquez de SalamancaR, BatlleAM, delC. The photodynamic and non-photodynamic actions of porphyrins. Braz J Med Biol Res, 1999; 32(3):255–266; doi: 10.1590/S0100-879X1999000300002
18.
SharmaD, SinghA, SafiS, et al.Porphyrins with combinations of 4-carboxyphenyl and 4-hydroxyphenyl substituents in meso-positions as anti-HIV-1 agents. Sci Rep, 2024; 14(1):10006; doi: 10.1038/s41598-024-60728-w
19.
HamblinMR, JoriG. Photodynamic inactivation of microbial pathogens: medical and environmental applications. The Royal Society of Chemistry; 2011; doi: 10.1039/9781849733083
20.
VzorovAN, DixonDW, TrommelJS, et al.Inactivation of Human Immunodeficiency Virus Type 1 by Porphyrins. Antimicrob Agents Chemother, 2002; 46(12):3917–3925; doi: 10.1128/aac.46.12.3917-3925.2002
21.
DairouJ, Vever-BizetC, BraultD. Interaction of sulfonated anionic porphyrins with HIV glycoprotein gp120: Photodamages revealed by inhibition of antibody binding to V3 and C5 domains. Antiviral Res, 2004; 61(1):37–47; doi: 10.1016/S0166-3542(03)00176-1
22.
McKenzieLK, BryantHE, WeinsteinJA. Transition metal complexes as photosensitisers in one- and two-photon photodynamic therapy. Coord Chem Rev, 2019; 379:2–29; doi: 10.1016/j.ccr.2018.03.020
23.
WongS-Y, SunRW-Y, ChungNP-Y, et al.Physiologically stable vanadium(IV) porphyrins as a new class of anti-HIV agents. Chem Commun (Camb), 2005(28):3544–3546; doi: 10.1039/B503535J
24.
LebedevaNS, GubarevYA, KoifmanMO, et al.The application of porphyrins and their analogues for inactivation of viruses. Molecules, 2020; 25(19):4368; doi: 10.3390/molecules25194368
25.
KwongPD, WyattR, RobinsonJ, et al.Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 1998; 393(6686):648–659; doi: 10.1038/31405
26.
HanQ, JonesJA, NicelyNI, et al.Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nat Commun, 2019; 10(1):2898; doi: 10.1038/s41467-019-10899-2
27.
DixonDW, GillAF, GiribabuL, et al.Sulfonated naphthyl porphyrins as agents against HIV-1. J Inorg Biochem, 2005; 99(3):813–821; doi: 10.1016/j.jinorgbio.2004.12.013
28.
VargasF, RivasC, ZoltanT, et al.Comparative Antiviral (HIV) Photoactivity of Metalized meso-Tetraphenylsulfonated Porphyrins. Med Chem, 2008; 4(2):138–145; doi: 10.2174/157340608783789167
29.
HamblinMR, HasanT. Photodynamic therapy: A new antimicrobial approach to infectious disease? Photochem Photobiol Sci, 2004; 3(5):436–450; doi: 10.1039/b311900a
30.
MirandaKE, RaposoLM. Characterizing HIV-1 tropism and key positions within the V3 loop using random forest analysis. Braz Arch Biol Technol, 2025; 68:e25230537; doi: 10.1590/1678-4324-2025230537
31.
TamamisP, FloudasCA. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Biophys J, 2013; 105(6):1502–1514; doi: 10.1016/j.bpj.2013.07.049
32.
BerlandaJ, KiesslichT, OberdannerCB, et al.Characterization of apoptosis induced by photodynamic treatment with hypericin in A431 human epidermoid carcinoma cells. J Environ Pathol Toxicol Oncol, 2006; 25(1–2):173–188; doi: 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.100
33.
LebedevaN, YurinaES, GubarevYA, et al.Interactions of tetracationic porphyrins with DNA and their effects on DNA cleavage. Spectrochim Acta A Mol Biomol Spectrosc, 2018; 199:235–241; doi: 10.1016/j.saa.2018.03.066
34.
ParisiAV, TurnerJ, TurnbullDJ, et al.Influence of summer daylight saving time on scattered erythemal solar ultraviolet exposures. J Photochem Photobiol B, 2008; 91(1):35–40; doi: 10.1016/j.jphotobiol.2008.01.010
35.
AgostinisP, BergK, CengelKA, et al.Photodynamic therapy of cancer: An update. CA Cancer J Clin, 2011; 61(4):250–281; doi: 10.3322/caac.20114
36.
SenguptaD, TimilsinaU, MazumderZH, et al.Dual activity of amphiphilic Zn(II) nitroporphyrin derivatives as HIV-1 entry inhibitors and in cancer photodynamic therapy. Eur J Med Chem, 2019; 174:66–75; doi: 10.1016/j.ejmech.2019.04.051
37.
SunRW-Y, YuW-Y, SunH, et al.In vitro inhibition of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase by gold(III) porphyrins. Chembiochem, 2004; 5(9):1293–1298; doi: 10.1002/cbic.200300773
38.
MalatestiN, MuniticI, JurakI. Porphyrin-based cationic amphiphilic photosensitisers as potential anticancer, antimicrobial and immunosuppressive agents. Biophys Rev, 2017; 9(2):149–168; doi: 10.1007/s12551-017-0257-7
39.
Wai-Yin SunR, MaD-L, WongEL-M, et al.Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans, 2007(43):4884; doi: 10.1039/b705079h
40.
YinH, LiY, ZhengY, et al.Photoinactivation of cell-free human immunodeficiency virus by hematoporphyrin monomethyl ether. Lasers Med Sci, 2012; 27(5):943–950; doi: 10.1007/s10103-011-1013-z
41.
SenguptaD, RaiM, Hoque MazumdarZ, et al.Two cationic meso-thiophenium porphyrins and their zinc-complexes as anti-HIV-1 and antibacterial agents under non-photodynamic therapy (PDT) conditions. Bioorg Med Chem Lett, 2022; 65:128699; doi: 10.1016/j.bmcl.2022.128699
42.
JiaS, WangS, LiS, et al.Specific modification and self-transport of porphyrins and their multi-mechanism cooperative antitumor studies. J Mater Chem B, 2021; 9(14):3180–3191; doi: 10.1039/D0TB02847A
43.
DoughertyTJ, GomerCJ, HendersonBW, et al.Photodynamic therapy. J Natl Cancer Inst, 1998; 90(12):889–905; doi: 10.1093/jnci/90.12.889
44.
KimTE, ChangJ-E. Recent studies in photodynamic therapy for cancer treatment: From basic research to clinical trials. Pharmaceutics, 2023; 15(9):2257; doi: 10.3390/pharmaceutics15092257
DorrP, WestbyM, DobbsS, et al.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 2005; 49(11):4721–4732; doi: 10.1128/AAC.49.11.4721-4732.2005
47.
KilbyJM, HopkinsS, VenettaTM, et al.Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of Gp41-mediated virus entry. Nat Med, 1998; 4(11):1302–1307; doi: 10.1038/3293
RobertsonCA, EvansDH, AbrahamseH. Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B, 2009; 96(1):1–8; doi: 10.1016/j.jphotobiol.2009.04.001
50.
GendelmanHE, ZhengJ, CoulterCL, et al.Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus—associated dementia. J Infect Dis, 1998; 178(4):1000–1007; doi: 10.1086/515693
51.
VallejoMCS, MouraNMM, GomesATPC, et al.The role of porphyrinoid photosensitizers for skin wound healing. Int J Mol Sci, 2021; 22(8):4121; doi: 10.3390/ijms22084121
52.
WeiX, DeckerJM, WangS, et al.Antibody Neutralization and Escape by HIV-1. Nature, 2003; 422(6929):307–312; doi: 10.1038/nature01470
53.
HartleyO, KlasseP, SattentauQ, et al.V3: HIV’s Switch-Hitter. AIDS Res Hum Retroviruses, 2005; 21(2):171–189; doi: 10.1089/aid.2005.21.171
54.
MausA, StraitL, ZhuD. Nanoparticles as delivery vehicles for antiviral therapeutic drugs. Eng Regen, 2021; 2:31–46; doi: 10.1016/j.engreg.2021.03.001
55.
KilbyJ, HopkinsS, VenettaT, et al.Penetrating the blood-brain barrier with new peptide–porphyrin conjugates having anti-HIV activity. Bioconjug Chem, 2021; 32(6):1067–1077; doi: 10.1021/acs.bioconjchem.1c00123
56.
de SouzaJF, SilvestriS, de SouzaPR, et al.Combined cyclodextrins and porphyrinoid derivatives in drug delivery systems: Developments and perspectives. Int J Pharm, 2026; 690:126544; doi: 10.1016/j.ijpharm.2025.126544
57.
TsolekileN, NelanaS, OluwafemiOS. Porphyrin as diagnostic and therapeutic agent. Molecules, 2019; 24(14):2669; doi: 10.3390/molecules24142669
58.
TabriziL, McGarryR, TurzanskaK, et al.Porphyrin-polymer as a photosensitizer prodrug for antimicrobial photodynamic therapy and biomolecule binding ability. Biomacromolecules, 2024; 25(12):7736–7749; doi: 10.1021/acs.biomac.4c01011
59.
OuyangQ, LiX, HeY, et al.A porphyrin metal–organic framework enhances photodynamic therapy through lymphatic circulation. J Mater Chem B, 2025; 13(28):8335–8347; doi: 10.1039/D4TB02199A
